GlassScriptPhysician profile
Thomas Allen Privett
NPI 1285632638
$14,625.36
in general payments reported to CMS, 2019-2025
44 companies · $3,922 in 2025
The $3,922 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.17 · 2021: $257 · 2022: $2,877 · 2023: $3,502 · 2024: $4,027 · 2025: $3,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,374.98 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,263.85 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,128.72 | 2022-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $996.86 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $797.00 | 2019-2025 | Briviact, Fintepla |
| Lilly USA, LLC | $725.23 | 2022-2025 | Emgality, Reyvow, Kisunla |
| Teva Pharmaceuticals USA, INC. | $712.54 | 2021-2025 | Ajovy, Austedo, Austedo Xr |
| Lundbeck LLC | $574.43 | 2022-2025 | Vyepti, Rexulti |
| Pfizer INC. | $549.74 | 2023-2025 | |
| Argenx US, INC. | $547.19 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $513.68 | 2022-2025 | Nuplazid |
| Sk Life Science, INC. | $454.27 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $395.42 | 2022-2025 | Rytary, Crexont |
| Eisai INC. | $390.87 | 2022-2025 | |
| Horizon Therapeutics Plc | $376.51 | 2022-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $357.26 | 2022-2025 | Ultomiris, Soliris |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $333.42 | 2022-2025 | Mavenclad, Mavenclad |
| Celgene Corporation | $323.90 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $224.93 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Tanabe Pharma America, INC. | $201.95 | 2023-2025 | Radicava |
| Biohaven Pharmaceutical Holding Company LTD. | $199.93 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $171.05 | 2024-2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $170.50 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Tg Therapeutics, INC. | $166.93 | 2025 | |
| Janssen Biotech, INC. | $165.95 | 2025 | |
| Aucta Pharmaceuticals, INC. | $115.33 | 2024-2025 | Motpoly Xr |
| Amgen INC. | $86.27 | 2024-2025 | Uplizna |
| Genzyme Corporation | $78.79 | 2023 | |
| Vanda Pharmaceuticals INC. | $66.48 | 2024-2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $57.86 | 2022-2025 | |
| Neurelis, INC. | $52.10 | 2025 | Valtoco |
| Cycle Pharmaceuticals INC | $47.28 | 2025 | Bafiertam, Tascenso Odt |
| Ani Pharmaceuticals, INC. | $46.72 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $45.41 | 2025 | Sunosi, Symbravo |
| Biohaven Pharmaceuticals, INC. | $38.63 | 2021 | |
| Impel Pharmaceuticals INC. | $36.95 | 2023 | Trudhesa |
| Allergan, INC. | $33.88 | 2022 | |
| Grifols USA, LLC | $32.52 | 2025 | Gamunex-C |
| Ipsen Biopharmaceuticals, INC | $28.62 | 2023 | Dysport |
| Mdd US Operations, LLC | $23.79 | 2025 | Gocovri |
| Mallinckrodt Hospital Products INC. | $23.63 | 2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $21.80 | 2025 | Trintellix |
| Insightec,INC | $18.01 | 2025 | Exablate |
| Currax Pharmaceuticals LLC | $14.90 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Privett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.